Incluye referencias bibliográficas e índice

Preface; Contents; Chapter 1: mGlu5 Signaling: A Target for Addiction Therapeutics?; 1.1 Introduction: Pharmacotherapy and Allosteric Modulators; 1.2 Negative Allosteric Modulators Reduce Drug Reward; 1.3 mGlu5 Receptors and Synaptic Plasticity; 1.4 mGlu5 Receptor Expression Changes Across Development of Addiction; 1.5 Cognitive Capacity Is Positively Correlated with Treatment Outcome for Substance Abuse Disorders; 1.6 Amnestic Effects of mGlu5 Inactivation; 1.7 Facilitatory Effects of mGlu5 Activation on Learning, Memory, and Extinction Processes; 1.8 Conclusion; References

3.3.2 Group II mGlu Receptors3.3.3 Group III mGlu Receptors; 3.4 Group I mGlu Receptors and Parkinson's Disease; 3.5 Group II mGlu Receptors and Parkinson's Disease; 3.6 Group III mGlu Receptors and Parkinson's Disease; 3.7 Concluding Remarks; References; Chapter 4: Metabotropic Glutamate 2 (mGlu2) Receptors and Schizophrenia Treatment; 4.1 Schizophrenia; 4.2 Metabotropic Glutamate Receptors; 4.3 Preclinical and Clinical Schizophrenia Assays with mGlu2/3 Receptor Agonists; 4.4 Environmental Events and mGlu2 Expression

4.5 Expression of mGlu2 and 5-HT2A as a GPCR Heteromer in Schizophrenia Treatment4.6 Conclusions; References; Chapter 5: mGlu5: A Metabotropic Glutamate Receptor at the Hub of Hippocampal Information Processing, Persistent Synaptic Plasticity, and Long-Term Memory; 5.1 Introduction; 5.2 Role of mGlu5 in Persistent Forms of Hippocampal Synaptic Plasticity and Memory; 5.2.1 Role of mGlu5 in Persistent LTP and LTP-Related Memory; 5.2.2 Role of mGlu5 in Persistent LTD and LTD-Related Memory; 5.3 Role of mGlu5 in Hippocampal Information Processing; 5.3.1 Neuronal Oscillations

5.3.2 The Role of mGlu5 in Place Fields5.3.3 The Special Case of the CA3 Region; 5.4 mGlu5 at the Hub of Hippocampal Function; References; Chapter 6: Neuroprotective Properties of Glutamate Metabotropic Glutamate Receptors in Parkinson's Disease and Other Brain Disorders; 6.1 Introduction; 6.2 MGluR Localization in the Basal Ganglia Circuitry; 6.3 Neuroprotective Effects of Group I mGluRs; 6.4 Neuroprotective Effects of Group II mGluRs in PD; 6.5 Neuroprotective Effects of Group III mGluRs in PD; 6.6 Neuroprotective Effects of mGluR-Related Drugs in Other Brain Diseases

Chapter 2: Supraspinal Metabotropic Glutamate Receptors: An Endogenous Substrate for Alleviating Chronic Pain and Related Affective Disorders2.1 Introduction; 2.2 mGluRs and Pain Processing; 2.3 Group I mGluRs; 2.4 Group II mGluRs; 2.5 Group III mGluRs; 2.6 Conclusion; References; Chapter 3: Metabotropic Glutamate Receptors and Parkinson's Disease: Basic and Preclinical Neuroscience; 3.1 Parkinson's Disease; 3.2 Rationale for Targeting mGlu Receptors for Parkinson's Disease; 3.3 Localization and Function of mGlu Receptors in the Basal Ganglia; 3.3.1 Group I mGlu Receptors

Metabotropic glutamate receptors (mGluRs) are members of the group C family of G-protein-coupled receptors. Eight different mGlu subtypes have been identified and classified into three groups based on amino acid sequence similarity, agonist pharmacology, and the signal transduction pathways to which they couple. They perform a variety of functions in the central and peripheral nervous systems, being involved in learning, memory, anxiety, and the perception of pain. They are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and cerebral cortex, as well as other parts of the brain and peripheral tissues. This volume comprises the latest contributions of experts in the field on the role of mGlu receptor in health and disease, following the 8th International meeting on these receptors.